Issue 23 - The Cancer Letter

Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.

SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.

LOGIN SUBSCRIBE NOW

SEARCH DATE

SEARCH TEXT

Cancel

OK

Cancel

OK

Delete Account

Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below

Big takeaway from ASCO:

Abrams: Only about 20-30 percent of the group might benefit from chemotherapy

Sharpless: NCI adds $10 million for NCTN and NCORP trials

Searching for Breast Cancer's “Extreme Survivors”

In Brief

J&J Innovation and Boston University form lung cancer research alliance

Kochevar to retire from Colorado Cancer Center

Funding Opportunities

Addario, Van Auken foundations announce 2018 Young Innovators Team Award

Clinical Roundup

New treatment combination improves outcomes for some patients with colorectal cancer

Exact Sciences, Mayo Clinic identify blood-based DNA biomarkers to diagnose hepatocellular carcinoma

Opdivo demonstrates superior RFS vs. Yervoy for patients with resected stage III or IV melanoma

Opdivo plus Yervoy provide QOL improvements in RCC

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login